In this study, DHM significantly improved the hepatic pathological status and inflammation levels in a mouse model of NAFLD by modulating the intestinal flora and inhibiting the TLR4/NF-κB signaling pathway. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.